| 1. |
- Al-Khalili Szigyarto, Cristina
(författare)
-
Duchenne Muscular Dystrophy : recent advances in protein biomarkers and the clinical application
- 2020
-
Ingår i: Expert Review of Proteomics. - : Informa UK Limited. - 1478-9450 .- 1744-8387. ; 17:5, s. 365-375
-
Forskningsöversikt (refereegranskat)abstract
- Introduction Early biomarker discovery studies have praised the value of their emerging results, predicting an unprecedented impact on health care. Biomarkers are expected to provide tests with increased specificity and sensitivity compared to existing measures, improve the decision-making process, and accelerate the development of therapies. For rare disorders, like Duchenne Muscular Dystrophy (DMD) such biomarkers can assist the development of therapies, therefore also helping to find a cure for the disease. Area covered State-of-the-art technologies have been used to identify blood biomarkers for DMD and efforts have been coordinated to develop and promote translation of biomarkers for clinical practice. Biomarker translation to clinical practice is however, adjoined by challenges related to the complexity of the disease, involving numerous biological processes, and the limited sample resources. This review highlights the current progress on the development of biomarkers, describing the proteomics technologies used, the most promising findings and the challenges encountered. Expert opinion Strategies for effective use of samples combined with orthogonal proteomics methods for protein quantification are essential for translating biomarkers to the patient's bed side. Progress is achieved only if strong evidence is provided that the biomarker constitutes a reliable indicator of the patient's health status for a specific context of use.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Fredolini, Claudia, et al.
(författare)
-
Immunocapture strategies in translational proteomics
- 2016
-
Ingår i: Expert Review of Proteomics. - : Taylor & Francis. - 1478-9450 .- 1744-8387. ; 13:1, s. 83-98
-
Forskningsöversikt (refereegranskat)abstract
- Aiming at clinical studies of human diseases, antibody-assisted assays have been applied to biomarker discovery and toward a streamlined translation from patient profiling to assays supporting personalized treatments. In recent years, integrated strategies to couple and combine antibodies with mass spectrometry-based proteomic efforts have emerged, allowing for novel possibilities in basic and clinical research. Described in this review are some of the field's current and emerging immunocapture approaches from an affinity proteomics perspective. Discussed are some of their advantages, pitfalls and opportunities for the next phase in clinical and translational proteomics.
|
|
| 5. |
- Gerdle, Björn, 1953-, et al.
(författare)
-
Proteomic studies of common chronic pain conditions-a systematic review and associated network analyses
- 2020
-
Ingår i: Expert Review of Proteomics. - : TAYLOR & FRANCIS LTD. - 1478-9450 .- 1744-8387. ; 17:6, s. 483-505
-
Forskningsöversikt (refereegranskat)abstract
- Introduction The lack of biomarkers indicating involved nociceptive and/or pain mechanisms makes diagnostic procedures problematic. Clinical pain research has begun to use proteomics. Areas covered This systematic review covers proteomic studies of chronic pain cohorts and in relation to clinical variables. Searches in three databases identified 96 studies from PubMed, 161 from Scopus and 155 from Web of Science database. Finally, 27 relevant articles were included. Network analyses based on the identified proteins were performed. Expert opinion Small pain cohorts were investigated and the number of studies per diagnosis and tissue is small. The use of proteomics in chronic pain research is exploratory and larger proteomic studies are needed. It will be necessary to standardize the descriptions of the pain cohorts investigated. There is a need to identify the mechanisms underlying the whole clinical presentation of specific chronic pain conditions. Multivariate methods capable of handling and identifying intercorrelated protein patterns must be applied. Rather than focusing on a few proteins, future studies should use network analyses to investigate interactions and biological processes. Proteomics in combination with bioinformatics have a huge potential to identify previously unknown panels of proteins involved in chronic pain and relevant when devising new pain control strategies.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Lindskog, Cecilia
(författare)
-
The potential clinical impact of the tissue-based map of the human proteome
- 2015
-
Ingår i: Expert Review of Proteomics. - : Informa UK Limited. - 1478-9450 .- 1744-8387. ; 12:3, s. 213-215
-
Tidskriftsartikel (refereegranskat)abstract
- Since the first draft of the human genome sequence was published, several attempts have been made to map the human proteome, the functional representation of the genome. One such initiative is the Human Protein Atlas project, which recently released a tissue-based map of the human proteome. The Human Protein Atlas is based on the combination of transcriptomics and antibody-based proteomics for mapping the human proteome down to the single cell level. The comprehensive publicly available database contains more than 13 million unique immunohistochemistry images and provides an excellent resource for exploration and investigation of future drug targets and disease biomarkers.
|
|
| 9. |
|
|
| 10. |
- Mondello, Stefania, et al.
(författare)
-
Extracellular vesicles : pathogenetic, diagnostic and therapeutic value in traumatic brain injury
- 2018
-
Ingår i: Expert Review of Proteomics. - : Taylor & Francis. - 1478-9450 .- 1744-8387. ; 15:5, s. 451-461
-
Forskningsöversikt (refereegranskat)abstract
- Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Accurate classification according to injury-specific and patient-specific characteristics is critical to help informed clinical decision-making and to the pursuit of precision medicine in TBI. Reliable biomarker signatures for improved TBI diagnostics are required but still an unmet need. Areas covered: Extracellular vesicles (EVs) represent a new class of biomarker candidates in TBI. These nano-sized vesicles have key roles in cell signaling profoundly impacting pathogenic pathways, progression and long-term sequelae of TBI. As such EVs might provide novel neurobiological insights, enhance our understanding of the molecular mechanisms underlying TBI pathophysiology and recovery, and serve as biomarker signatures and therapeutic targets and delivery systems. Expert commentary: EVs are fast gaining momentum in TBI research, paving the way for new transformative diagnostic and treatment approaches. Their potential to sort out TBI variability and active involvement in the mechanisms underpinning different clinical phenotypes point out unique opportunities for improved classification, risk-stratification ad intervention, harboring promise of predictive, personalized, and even preemptive therapeutic strategies. Although a great deal of progress has been made, substantial efforts are still required to ensure the needed rigorous validation and reproducibility for clinical implementation of EVs.
|
|
